Publication:
An update on the exploratory use of curcumin in neuropsychiatric disorders

Simple item page
dc.affiliation.dptoUC3M. Departamento de Bioingenieríaes
dc.affiliation.grupoinvUC3M. Grupo de Investigación: Biomedical Imaging and Instrumentation Groupes
dc.contributor.authorLamanna Rama, Nicolás
dc.contributor.authorRomero Miguel, Luis Diego
dc.contributor.authorDesco Menéndez, Manuel
dc.contributor.authorSoto Montenegro, Mª Luisa
dc.contributor.funderComunidad de Madrides
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)es
dc.date.accessioned2023-01-25T08:29:39Z
dc.date.available2023-01-25T08:29:39Z
dc.date.issued2022-02
dc.descriptionThis article belongs to the Special Issue Dietary Antioxidants against Neurodegenerative Diseases.en
dc.description.abstractCurcumin is a polyphenol extracted from the rhizome of the turmeric plant. Beyond its common use as a culinary spice in Eastern Asia, curcumin has been proposed as a therapeutic compound due to its antioxidant, anti-inflammatory and neuroprotective properties. Thus, its efficacy has been evaluated in various inflammatory-based psychiatric disorders, such as schizophrenia, depression, or autism. Our aim is to review those preclinical and clinical studies carried out in psychiatric disorders whose therapeutic approach has involved the use of curcumin and, therefore, to discern the possible positive effect of curcumin in these disorders. Preclinical studies and completed clinical trials of curcumin for psychiatric disorders published from January 2005 to October 2021 were identified through searching relevant databases until 31st October 2021. Sixty-five preclinical studies and 15 clinical trials and open-label studies were selected. Results showed a bias toward studies in depression and, to a lesser extent, schizophrenia. In all disorders, the results were positive in reducing psychiatric deficits. Despite the considerable number of beneficial outcomes reported, the small number of trials and the heterogeneity of protocols make it difficult to draw solid conclusions about the real potency of curcumin in psychiatric disorders.en
dc.description.sponsorshipM.L.S.-M. was supported by the Ministerio de Ciencia, Innovación y Universidades, Instituto de Salud Carlos III (project number PI17/01766, and grant number BA21/00030), co-financed by the European Regional Development Fund (ERDF), "A way to make Europe", CIBER de Salud Mental (project number CB07/09/0031), Delegación del Gobierno para el Plan Nacional sobre Drogas (project number 2017/085); and Fundación Alicia Koplowitz (FAK16/01). D.R.-M. was supported by Consejería de Educación e investigación, Comunidad de Madrid, co-funded by the European Social Fund "Investing in your future" (grant, PEJD-2018-PRE/BMD-7899). N.L.-R. was supported by the Instituto de investigación Sanitaria Gregorio Marañón, "Programa Intramural de Impulso a la I+D+I 2019". The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505).en
dc.format.extent27
dc.identifier.bibliographicCitationLamanna-Rama, N., Romero-Miguel, D., Desco, M. & Soto-Montenegro, M. L. (2022). An update on the exploratory use of curcumin in neuropsychiatric disorders. Antioxidants, 11(2), 353.en
dc.identifier.doihttps://doi.org/10.3390/antiox11020353
dc.identifier.issn2076-3921
dc.identifier.publicationfirstpage1
dc.identifier.publicationissue2, 353
dc.identifier.publicationlastpage27
dc.identifier.publicationtitleAntioxidantsen
dc.identifier.publicationvolume11
dc.identifier.urihttps://hdl.handle.net/10016/36356
dc.identifier.uxxiAR/0000031162
dc.language.isoengen
dc.publisherMDPI
dc.relation.projectIDGobierno de España. PI17/01766es
dc.relation.projectIDGobierno de España. BA21/00030es
dc.relation.projectIDComunidad de Madrid. PEJD-2018-PRE/BMD-7899es
dc.relation.projectIDGobierno de España. SEV-2015-0505es
dc.rights© 2022 by the authors.en
dc.rightsAtribución 3.0 España*
dc.rights.accessRightsopen accessen
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subject.ecienciaBiología y Biomedicinaes
dc.subject.otherAutismen
dc.subject.otherCurcuminen
dc.subject.otherDepressionen
dc.subject.otherInflammationen
dc.subject.otherObsessive compulsive disorderen
dc.subject.otherOxidative stressen
dc.subject.otherPsychiatric disordersen
dc.subject.otherSchizophreniaen
dc.titleAn update on the exploratory use of curcumin in neuropsychiatric disordersen
dc.typeresearch article*
dc.type.hasVersionVoR*
dspace.entity.typePublication
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Update_A_2022.pdf
Size:
1.11 MB
Format:
Adobe Portable Document Format
Download
Collections
DBIAB - BIIG - Journal Articles